



Since January 2020 Elsevier has created a COVID-19 resource centre with free information in English and Mandarin on the novel coronavirus COVID-19. The COVID-19 resource centre is hosted on Elsevier Connect, the company's public news and information website.

Elsevier hereby grants permission to make all its COVID-19-related research that is available on the COVID-19 resource centre - including this research content - immediately available in PubMed Central and other publicly funded repositories, such as the WHO COVID database with rights for unrestricted research re-use and analyses in any form or by any means with acknowledgement of the original source. These permissions are granted for free by Elsevier for as long as the COVID-19 resource centre remains active.



ELSEVIER

Contents lists available at ScienceDirect

International Journal of Infectious Diseases

journal homepage: www.elsevier.com/locate/ijidINTERNATIONAL
SOCIETY
FOR INFECTIOUS
DISEASES

Medical Imagery

Encephalopathy in severe SARS-CoV2 infection: Inflammatory or infectious?



ARTICLE INFO

Article history:

Received 19 April 2020

Received in revised form 5 July 2020

Accepted 19 July 2020

Keywords:

SARS-CoV2

COVID-19

Coronavirus

Neuroradiological lesions

Neurological symptoms

Encephalopathy

ABSTRACT

Concerning the letter by Moriguchi et al., we describe our experience with a case of encephalopathy with and atypical damage on magnetic resonance imaging (MRI) in a patient with severe infection due to the SARS-CoV2 virus. A 56-year-old woman, without previous pathologies, developed cough, fever, and respiratory failure for five days, after returning from a 6-day trip to Venice. Chest radiography shows a large bilateral interstitial infiltrate. In the first 24 hours, she was admitted to the Intensive Care Unit (ICU) for severe respiratory failure and positive protein chain reaction-PCR in nasal exudate. She needed intubation for ten days. In the first 48 hours outside the ICU, she developed an acute confusional syndrome (hyperactive delirium). Neurological examination showed temporal-spatial disorientation and incoherent fluent speech.

An electroencephalogram (EEG) showed generalized hypovoltic activity. Cranial magnetic resonance imaging showed a bilateral and symmetrical increase in the supratentorial white matter's signal intensity, with a discrete thickening of both temporal lobes, with a slight increase in signal intensity and a sequence of normal diffusion. The lumbar puncture showed no changes (glucose 71 mg/dL, protein 30 mg/dL, 1 leukocyte). Within 72 hours of starting symptoms, she was neurologically asymptomatic. Our final diagnosis was an inflammatory encephalopathy related to a SARS-CoV2 infection.

© 2020 The Author(s). Published by Elsevier Ltd on behalf of International Society for Infectious Diseases. This is an open access article under the CC BY-NC-ND license (<http://creativecommons.org/licenses/by-nc-nd/4.0/>).

The appearance of SARS-CoV2 was described in December 2019 in China, but it was not until March 2020 when the pandemic reached Spain. Although this virus mainly presents a respiratory involvement, we have observed the appearance of neurological symptoms (headache, myalgia, hyposmia/anosmia, dysgeusia, insomnia) and diseases (stroke, encephalitis, or Guillain-Barré syndrome) (Mao et al., 2020; Li et al., 2020; Helms et al., 2020; De Melo Espindola et al., 2020).

Concerning the letter by Moriguchi et al., we describe our experience with a case of encephalopathy with an atypical damage on magnetic resonance imaging (MRI) (Moriguchi et al., 2020).

A 56-year-old woman, without previous pathologies, came to the Emergency Department (ED) for cough, fever, and respiratory failure for five days, after returning from a 6-day trip to Venice. Chest radiography shows a large bilateral interstitial infiltrate. The analysis also highlighted lactate dehydrogenase: 537 U/L, C-reactive protein: 76.7 mg/L, D-dimer: 1041 ng/ml, Interleukin-6: 26, and procalcitonin levels: 0.07 ng/ml. Arterial blood gas showed: pH 7.50, pO₂: 32.9, and pCO₂: 29.4. She did not develop leukocytosis nor kidney failure.

In the first 24 hours, she was admitted to the Intensive Care Unit (ICU) for acute severe respiratory failure, with 70% oxygen saturation despite oxygen therapy, and extensive bilateral pneumonia secondary to SARS-CoV2 (positive protein chain reaction-PCR in nasal exudate). She required intubation for ten days, and

received ceftriaxone, ritonavir/lopinavir, corticosteroids, and hydroxychloroquine, with clinical improvement. In the first 48 hours outside the ICU, she developed an acute confusional syndrome (hyperactive delirium). On neurological examination, she exhibited temporal-spatial disorientation, incoherent fluent speech, without other neurological symptoms.

An electroencephalogram (EEG) was performed in the first 48 hours, showing generalized hypovoltic activity, not related to the drugs present at that time. Cranial magnetic resonance imaging was also performed, which showed a bilateral and symmetrical increase in the signal intensity of the supratentorial white matter, with a discrete thickening of both temporal lobes with a slight increase in signal intensity, and a sequence of normal diffusion (Figure 1). The lumbar puncture showed no changes (glucose 71, protein 30, 1 leukocyte). Within 72 hours of starting symptoms, she was neurologically asymptomatic. Our final diagnosis was an inflammatory encephalopathy related to SARS-CoV2 infection.

We consider the possibility that the demonstrated radiological lesions are secondary to an inflammatory reaction, instead of a tissue injury due to viral invasion.

Conflict of interest, funding source, and ethical approval

The authors declare the absence of conflict of interests and agree with the contents of the manuscript. All the data are original,

<https://doi.org/10.1016/j.ijid.2020.07.020>

1201-9712/© 2020 The Author(s). Published by Elsevier Ltd on behalf of International Society for Infectious Diseases. This is an open access article under the CC BY-NC-ND license (<http://creativecommons.org/licenses/by-nc-nd/4.0/>).




Figure 1. Increased signal intensity of the supratentorial white matter bilaterally and symmetrically (1A), with a slight thickening and increased signal of both temporal lobes. There is no restriction on diffusion sequence (1B).

they have not been sent for evaluation to any other journal. The data have not been presented in any congress or conferences. No author has received partial or total funding from any public or private institution in relation to this article.

Authors declare the absence of study sponsors in the study design, in the collection analysis, interpretation of data, and the decision to submit the manuscript for publication. We did not have any writing assistance.

This work has been evaluated and approved by the Medical Investigation Commission of our center in April 2020.

References

- De Melo Espíndola O, Siqueira M, Nascimento Soares C, Sales Dantas de Lima MA, Celestino Bezerra Leite AC, Queiroz Campos Araujo A, et al. Patients with COVID-19 and neurological manifestations show undetectable SARS-CoV2 RNA levels in the cerebrospinal fluid. *Int J Infect Dis* 2020;96:567–9.
- Helms J, Kremer S, Merdji H, Clere-Jehl R, Schenk M, Kummerlen C, et al. Neurologic features in severe SARS-CoV-2 infection. *New Engl J Med* 2020; in press.
- Li YC, Bai WZ, Hashikawa T. The neuroinvasive potential of SARS-CoV2 may play a role in the respiratory failure of COVID-19 patients. *J Med Virol* 2020;1–4.
- Ling Mao, M. Wang, S. Chen, Q. He, J. Chang, C. Hong, et al. Neurological manifestations of hospitalized patients with COVID-19 in Wuhan, China: a retrospective case series study. *JAMA* in press. <https://doi.org/10.1101/2020.02.22.20026500>.
- Moriguchi T, Harii N, Goto J, Harada D, Sugawara H, Takamino J, et al. A first case of meningitis/encephalitis associated with SARS-Coronavirus-2. *Int J Infect Dis* 2020;94:55–8.

María José Abenza-Abildúa PhD^{a,*}
 Susana Novo-Aparicio MD^b
 Raúl Moreno-Zabaleta PhD^c
 María Carmen Algarra-Lucas^a
 Blas Rojo Moreno-Arcones MD^c
 Miguel Ángel Salvador-Maya MD^c
 Francisco José Navacerrada-Barrero MD^a
 Joaquín Ojeda-Ruiz de Luna MD^a

Carlos Pérez-López MD^d
 José María Fraile-Vicente MD^g
 Inés Suárez-García PhD^e
 Eugenio Suarez-Gisbert PhD^f
 Juan Antonio Palacios-Castaño PhD^f
 María Teresa Ramirez-Prieto PhD^c

^aNeurology Department, Infanta Sofía University Hospital, Madrid, Spain

^bNeuroradiology Department, Infanta Sofía University Hospital, Madrid, Spain

^cPneumology Department, Infanta Sofía University Hospital, Madrid, Spain

^dNeurosurgery Department, La Paz University Hospital, Madrid, Spain

^eInternal Medicine-Infectious Diseases Department, Infanta Sofía University Hospital, Madrid, Spain

^fPsychiatry Department, Infanta Sofía University Hospital, Madrid, Spain

^gPalliative Care Department, Infanta Sofía University Hospital, Madrid, Spain

* Corresponding author at: Neurology Department, Infanta Sofía University Hospital, Paseo de Europa 34, 28702, San Sebastián de los Reyes, Madrid, Spain.

E-mail addresses: mjose.abenza@salud.madrid.org (M. Abenza-Abildúa), susana.novo@salud.madrid.org (S. Novo-Aparicio), raul.morenoza@salud.madrid.org (R. Moreno-Zabaleta), mcarmen.algarra@salud.madrid.org (M. Algarra-Lucas), blas.rojo@salud.madrid.org (B. Rojo Moreno-Arcones), miguelangel.salvador@salud.madrid.org (M. Salvador-Maya),

francisco.navacerra@salud.madrid.org (F. Navacerrada-Barrero),
ojedamd@gmail.com (J. Ojeda-Ruíz de Luna),
cperezhulp@yahoo.es (C. Pérez-López),
josemaria.fraile@salud.madrid.org (J. Fraile-Vicente),
imaria.suarez@salud.madrid.org (I. Suárez-García),
ugelot@gmail.com (E. Suarez-Gisbert),

jantonio.palacios@salud.madrid.org (J. Palacios-Castaño),
mtramirezp@salud.madrid.org (M. Ramirez-Prieto).

Received 19 April 2020

Received in revised form 5 July 2020

Accepted 19 July 2020